Trial
NCT06528210
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
OHSU Knight Cancer Institute
Collaborators
Merck Sharp & Dohme LLC; Oregon Health and Science University
Condition
High Risk Prostate Carcinoma
Intervention
Gonadotropin Releasing Hormone Agonists and Antagonists
Why stopped
Loss of funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-23